Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Initiated symbols : Azn save search
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published: 2023-12-18 (Crawled : 00:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 4.3K
|
Health Technology
|
| O: 1.03%
H: 1.08%
C: 0.73%
breast cancer trials plus initiated
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
Published: 2023-01-30 (Crawled : 14:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 4.3K
|
Health Technology
|
| O: 1.3%
H: 0.06%
C: -0.81%
lung trial cancer initiated
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 4.3K
|
Health Technology
|
| O: -1.4%
H: 0.4%
C: -0.7%
trial cancer negative initiated breast cancer phase 3
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2021-12-23 (Crawled : 14:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 4.3K
|
Health Technology
|
| O: -1.0%
H: 0.71%
C: 0.24%
enhertu trial cel lung cancer cancer phase 3 initiated her2- her2
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
AZN | $68.53 0.39% 0.39% 4.3K
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
risk trial positive cancer phase 3 breast cancer initiated her2- her2
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 4.3K
|
Health Technology
|
| O: -1.46%
H: 0.33%
C: -0.32%
positive cancer phase 3 breast cancer trial initiated hormone her2+ her2- her2 metastatic breast cancer
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 4.3K
|
Health Technology
|
| O: 0.11%
H: 0.03%
C: -0.27%
lung cancer collaboration cancer trial initiated keytruda
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
AGBA | $1.44 260.0% 40M
|
Finance
BPTH | $6.25 92.9% 20M
|
Health Technology
EGOX | $0.0447 39.25% 24M
|
ALRN | $5.67 33.41% 110K
|
Health Technology
BNTC | $5.91 23.13% 1.3M
|
Health Technology
XPON | $2.33 20.73% 410K
|
BRSH | $0.0515 15.99% 12M
|
n/a
VTNR S | $1.12 14.38% 470K
|
Industrial Services
GGE | $0.0332 13.7% 18M
|
DXYZ 4 | $33.49 13.41% 210K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.